Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-122 + Lucentis in Wet AMD
NCT03211234Phase 2Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of carotuximab in exudative macular degeneration (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Mean Change From Baseline in Best Corrected Visual Acuity at 24 weeks. Started Jul 2017; status: completed.
02
Drugs
carotuximab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03211234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211234.